Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary Chungnam National University Sejong Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
Brings Benefits of MRI-Guided Radiation Therapy Closer to Home for Cancer Patients in Korea CLEVELAND , Sept. 24, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that Chungnam National University Sejong Hospital in Sejong, South Korea has begun patient treatments with the MRIdian
Toggle Summary ViewRay® to Participate in Upcoming Investor Conferences
CLEVELAND , Sept. 4, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in three upcoming virtual investor conferences.     Event :             Cantor Virtual Global Healthcare Conference   Format:   Virtual 1x1 Meetings Date:               
Toggle Summary 10,000th Patient Receives Treatment with ViewRay's MRIdian System
MRI-Guided Radiation Therapy Brings Cutting-Edge Cancer Treatment to Patients Around the World CLEVELAND , Sept. 1, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that 10,000 patients have been treated to date using the company's MRIdian ® MRI-Guided Radiation Therapy System,
Toggle Summary ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer
ViewRay, the GenesisCare Foundation and the Pancreatic Cancer Research Fund Work Together to Provide MRIdian Radiation Therapy at No Cost to NHS Pancreatic Cancer Patients CLEVELAND , Aug. 27, 2020 /PRNewswire/ --– ViewRay, Inc. (Nasdaq: VRAY) announced today that the GenesisCare Foundation's

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select